Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Anti-infectives Market

Veterinary Anti-infectives Market Size

Report ID: GMI12126
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Veterinary Anti-infectives Market Size

The veterinary anti-infectives market size was valued at USD 5.4 billion in 2023 and is estimated to grow at 3.5% CAGR from 2024 to 2032. The veterinary anti-infective market has grown significantly, largely due to the increasing incidence of infectious diseases in livestock and companion animals.

To get key market trends

Download Free Sample

The intensification of livestock farming, driven by rising global demand for meat and animal-based products, has heightened the risk of infections stemming from close living conditions. For instance, according to the World Health Organization (WHO), there are over 200 recognized zoonotic diseases, including bacterial, viral, and parasitic infections. Notably, 60% of infectious diseases are zoonotic in origin, and 75% of emerging human pathogens stem from animals. This trend drives the demand for anti-infectives, which are essential in controlling and preventing zoonotic outbreaks, prompting increased investment from governments, farmers, and pet owners.

Anti-infectives are crucial for controlling bacterial, viral, and fungal infections, preventing disease outbreaks that could lead to substantial economic losses in agriculture, and ensuring animal welfare within the companion animal sector. These treatments play a vital role in maintaining animal health across various species and settings. Additionally, the rise in pet ownership has intensified the focus on animal healthcare, further boosting the demand for effective treatments.

Veterinary anti-infectives are pharmaceutical agents used to prevent, treat, and control infections caused by bacteria, viruses, fungi, and parasites in animals, including livestock and companion animals. These products are essential for maintaining animal health and reducing the spread of zoonotic diseases that can be transmitted to humans. The veterinary anti-infectives market includes various types of drugs, such as antibiotics, antivirals, antifungals, and antiparasitics, which are widely used in both preventive care and the treatment of infectious diseases in veterinary medicine.

Veterinary Anti-infectives Market Report Attributes
Report Attribute	Details
Base Year:	2023
Veterinary Anti-infectives Market Size in 2023:	USD 5.4 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	3.5%
2032 Value Projection:	USD 7.4 Billion
Historical Data for:	2021 - 2023
No. of Pages:	150
Tables, Charts & Figures:	164
Segments covered:	Animal Type, Product Type, Route of Administration, Distribution Channel, and Region
Growth Drivers:	Rising incidence of zoonotic diseases among animals Growing advancements in veterinary medicines Increasing demand for meat and animal products Growing government initiatives to control animal diseases
Pitfalls & Challenges:	Rising concerns over antibiotic resistance Stringent regulatory challenges

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The veterinary anti-infectives industry was valued at USD 5.4 billion in 2023 and is estimated to grow at a 3.5% CAGR from 2024 to 2032, driven by the increasing incidence of infectious diseases in livestock and companion animals.

The livestock animals segment accounted for the largest revenue in 2023 and is expected to maintain its dominance with a 3.4% CAGR through the forecast period, due to the growing need for disease prevention and management in large-scale animal farming.

U.S. veterinary anti-infectives industry was valued at USD 2 billion in 2023 and is anticipated to show considerable growth over the analysis period, driven by advanced healthcare infrastructure, substantial R&D investments, and a high prevalence of infectious diseases.

Key players in the market include Aspen Veterinary Resources, Boehringer Ingelheim International, Ceva, Dechra Pharmaceuticals, Elanco, Merck & Co, Norbrook, Phibro Animal Health, Vetoquinol S.A., Virbac, and Zoetis.